BGI Health and ACIBADEM Healthcare Group Genetic Diagnostic Center in cooperation with Genoks Company Molecular Biology, signed a Memorandum of Understanding (MoU) for jointly introducing the advanced genetic testing technologies to Turkey and improving Turkish reproductive healthcare. This partnership will foster the applications of genetic testing technologies in the areas of Monogenic disorders, personalized medical healthcare, birth defects that cause terrible diseases, among others.
With the fast development of scientific technologies, there are a variety of testing tools that parents can use to look into their baby's future health, or to predict some of most serious hereditary diseases. Among them, genetic testing is the latest and most sophisticated of techniques used to detect gene variants associated with a specific disease or condition. In the clinical applications, genetic testing technologies can be performed to confirm a suspected diagnosis, to predict the possibility of future illness, to detect the presence of a carrier state in unaffected individuals (whose children may be at risk), and to predict response to therapy.
Considering the potential and importance of genetic testing, ACIBADEM Healthcare Group Genetic Diagnostic Center and BGI Health entered collaboration for further accelerating its clinical applications, and benefiting the reproductive health of Turkish population. This partnership will combine BGI Health's powerful genetic testing platform and genomic knowledge with Acibadem hospital's splendid clinical expertise and experience. The collaboration will involve Non-invasive Fetal Trisomy testing (NIFTY), Monogenic disorder genetic testing, Exome-seq based personalized medical healthcare, HLA genotyping, among others.
"Through the powerful combination of complementary advantages, the cooperation between BGI and ACIBADEM Healthcare Group Genetic Diagnostic Center will be conductive to advance the clinical applications of genetic testing technologies and develop better solutions to address the challenges of hereditary diseases." said Dr. Ning Li, Director of BGI Europe. "Supported by our international partners, I believe we are likely to change the current practice of medicine and public health by facilitating more accurate, sophisticated and cost-effective genetic testing in Turkey and other European countries. "
"ACIBADEM Healthcare Group Genetic Diagnostic Center provides state-of-the-art cytogenetic and molecular genetic analysis for local and international prestigious hospitals therewithal ACIBADEM Hospitals. We sincerely believe BGI Health will definitely accelerate and expand our capacity to respond the complex diagnostic challenges, multi-genic and multifactorial diseases and conducting clinical research.
I believe our business will continue to provide the same high quality products and service with the honored reputation of yours and this partnership would effect our studies in the effective and efficient manner of conducting business." said Prof. Dr. M. Cengiz YAKICIER Director of ACIBADEM Healthcare Group Genetic Diagnostic Center.
New genetic model offers insights into breast cancer metastasis